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AbstrACt
Introduction Delayed prescribing can be a useful 
strategy to reduce antibiotic prescribing, but it is not 
clear for whom delayed prescribing might be effective. 
This protocol outlines an individual patient data (IPD) 
meta-analysis of randomised controlled trials (RCTs) 
and observational cohort studies to explore the overall 
effect of delayed prescribing and identify key patient 
characteristics that are associated with efficacy of 
delayed prescribing.
Methods and analysis A systematic search of the 
databases Cochrane Central Register of Controlled 
Trials, Ovid MEDLINE, Ovid Embase, EBSCO CINAHL 
Plus and Web of Science was conducted to identify 
relevant studies from inception to October 2017. 
Outcomes of interest include duration of illness, 
severity of illness, complication, reconsultation and 
patient satisfaction. Study authors of eligible papers 
will be contacted and invited to contribute raw IPD 
data. IPD data will be checked against published data, 
harmonised and aggregated to create one large IPD 
database. Multilevel regression will be performed 
to explore interaction effects between treatment 
allocation and patient characteristics. The economic 
evaluation will be conducted based on IPD from the 
combined trial and observational studies to estimate 
the differences in costs and effectiveness for delayed 
prescribing compared with normal practice. A decision 
model will be developed to assess potential savings 
and cost-effectiveness in terms of reduced antibiotic 
usage of delayed prescribing and quality-adjusted life 
years.
Ethics and dissemination Ethical approval was 
obtained from the University of Southampton Faculty 
of Medicine Research Ethics Committee (Reference 
number: 30068). Findings of this study will be 
published in peer-reviewed academic journals as 
well as General Practice trade journals and will be 
presented at national and international conferences. 
The results will have important public health 
implications, shaping the way in which antibiotics 
are prescribed in the future and to whom delayed 
prescriptions are issued.
PrOsPErO registration number CRD42018079400.
IntrOduCtIOn 
Antimicrobial resistance is a cause for great 
concern prompting calls for action at the 
local, national and international level to 
prevent ‘overuse, misuse and abuse’ of antibi-
otics,1 particularly in primary care where anti-
biotics are most prescribed.2 About 60% of 
antibiotics prescribed in primary care are for 
respiratory tract infections (RTIs).3 However, 
most infections are self-limiting, symptom-
atic benefit from antibiotics is modest4–6 
and patients prescribed antibiotics for RTIs 
are more likely to carry antibiotic resistant 
commensal bacteria and develop resistant 
infections.7 
The Standing Medical Advisory Committee 
report recommends that the fewest number 
of antibiotic courses should be prescribed for 
the shortest period possible.8 However, in a 
strengths and limitations of this study
 ► This study uses individual patient data (IPD) from 
randomised controlled trials and observation-
al studies to investigate the clinical effectiveness 
and potential cost-savings of a delayed antibiotic 
prescribing, both overall and for key subgroups of 
people.
 ► IPD provides sufficient statistical power to explore 
interactions between treatment groups and patient 
characteristics.
 ► The IPD will only include data from studies for which 
the data are available.
 ► Observational studies will use propensity score ap-
proach to adjust for confounding by indication on 
measured covariates.
 ► Findings from this study may inform GPs decisions 
on prescribing and increase use of appropriate de-
layed prescribing which in turn can help to reduce 
antibiotic consumption and antimicrobial resistance.
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primary care context, it can be difficult to tell whether 
antibiotics are appropriate for an individual patient. It is 
not always clear which patients are at risk of prolonged 
illness or developing complications nor whether the RTI 
is bacterial or viral in nature. Point of care tests such as C 
reactive protein and clinical scores both show promise in 
helping to guide GP management decisions.9–12 Delayed 
prescribing is a useful strategy that may be used on its own 
or in conjunction with clinical scores and point of care 
testing. It allows the patient to collect a prescription to 
be taken if their symptoms do not start to improve within 
a specific duration of their initial consultation, providing 
a potential aid to negotiating treatment acceptable to 
the patient and provider while reducing inappropriate 
prescribing.13 14 Delayed prescribing is recognised as 
part of the toolkit available to GPs to help reduce antibi-
otic use, especially in the context of consultations where 
patients expect to receive an antibiotic prescription and is 
part of the National Institute for Health and Care Excel-
lence guidelines.3 A recent large prospective primary care 
cohort (MRC DESCARTE) demonstrated that delayed 
prescription was likely to be as effective as immediate 
antibiotic in reducing complications and more effective 
at reducing reconsultations.4
While in some situations delayed antibiotic prescribing 
is appropriate, for other patients it may be unsuitable 
and controversial.15 It is important to understand which 
subgroups of patients may require immediate antibi-
otics to avoid complications and which patients might 
benefit from a delayed or no prescribing strategy.4 A 
2013 Cochrane review16 of 10 trials found that a delayed 
prescribing strategy was not significantly different to 
immediate prescribing in terms of clinical outcomes for 
cough and cold. In patients with acute otitis media and 
sore throat immediate antibiotics were more effective 
than delayed for reducing fever, pain and malaise in some 
studies. However, the review noted a high level of hetero-
geneity between studies made combining them in a tradi-
tional meta-analysis difficult and did not allow sufficient 
power for the examination of subgroups or complications 
either in meta-analysis or in meta-regression.
Where aggregation is possible, a traditional meta-anal-
ysis or even meta-regression can be used to determine 
the overall main effect of delayed antibiotic prescription. 
Although such techniques can also be used to explore how 
effect varies across study characteristics, these techniques 
lack statistical power and are prone to confounding as 
patient-level characteristics are not taken into account.17 
An individual patient data (IPD) meta-analysis is consid-
ered the gold standard for meta-analyses and can over-
come the limitations of meta-analysis of aggregate data. In 
an IPD meta-analysis, original data for all participants in 
each study are obtained and synthesised. This allows suffi-
cient statistical power18 to explore interactions between 
treatment groups and patient characteristics. This 
would allow us to identify key groups in which delayed 
prescribing or no prescribing might be inadvisable due 
to longer durations of illness, greater severity of illness 
or higher risk of complications/reconsultation. These 
findings may inform GPs decisions on prescribing and 
increase use of appropriate delayed prescribing which in 
turn can help to reduce antibiotic consumption and anti-
microbial resistance.
This protocol describes an IPD meta-analysis of both 
randomised controlled trials (RCTs) and observational 
cohort studies of delayed antibiotic prescribing for acute 
respiratory infections. Although RCTs represent the ‘gold 
standard’ design for assessing the impact of an interven-
tion, the participants in these studies may differ systemat-
ically from the patients encountered in everyday clinical 
practice due to the inclusion criteria. By including obser-
vational studies in a meta-analysis, with suitable tech-
niques to control for potential confounding by indication, 
it may be possible to obtain better estimates of the effect 
of delayed prescribing in routine practice.
MEthOds
Aims and objectives
This IPD study will investigate the clinical effective-
ness and potential cost-savings of a delayed antibiotic 
prescribing approach, both overall and for key subgroups 
of patients. The study started in October 2017 and is due 
to be completed in September 2020.
The objectives of this study are as follows:
 ► To achieve more accurate estimates of the clinical 
effectiveness of a delayed prescribing strategy on the 
primary outcome, symptom severity, by harmonising 
the outcomes from all trials and observational studies 
which have included this strategy.
 ► To estimate the clinical effectiveness of delayed 
prescribing for secondary outcomes: duration of 
illness, development of complications, reconsultation 
and patient satisfaction.
 ► To explore whether there are key subgroups 
(informed by the literature and described below) for 
whom delayed antibiotic prescribing may or may not 
be beneficial. Subgroups will be: prior duration of 
illness (above/below median for the condition), age 
(under 16 years, 16–64 years, age over 65 years), fever 
at baseline consultation (>37.5°C), comorbid condi-
tions including lung comorbidity such as asthma or 
chronic obstructive pulmonary disease (COPD) and 
severity of symptoms at baseline consultation. The 
effectiveness of delayed antibiotic prescribing for 
subgroups of symptom complexes such as cough 
(acute bronchitis), pharyngitis or otitis media will also 
be explored.
 ► To investigate whether symptom trajectories are influ-
enced by antibiotic prescribing/consumption.
 ► To estimate the costs of treatment of patients with 
RTIs (from the UK National Health Service (NHS) 
and Personal Social Services (PSS) perspective data) 
and investigate any potential cost-savings and cost-ef-
fectiveness in terms of antibiotic usage of delayed anti-
biotic prescriptions compared with antibiotic use.
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 ► To identify priorities for future delayed prescribing 
research.
study approach
A full systematic review will be conducted to identify and 
select eligible papers. Study authors of eligible papers will 
be contacted and invited to contribute raw data.
systematic review to identify eligible papers
Eligibility criteria
Design: RCTs or eligible observational cohort studies.
Population: all patients attending primary, ambulatory 
or acute care settings with a RTI.
Intervention: delayed antibiotic prescription.
Comparator: immediate antibiotic prescription or no 
antibiotic prescription.
Outcomes: severity of illness (symptom severity), dura-
tion of illness, complication, reconsultation, patient satis-
faction, costs and quality of life.
Studies on antibiotic prescribing that are not an RCT or 
observational cohort (eg, survey or cross-sectional studies 
and case–control studies) will be excluded. Studies of 
hospital inpatients are also excluded.
search strategy for identification of studies
A systematic search of the databases Cochrane Central 
Register of Controlled Trials, Ovid MEDLINE, Ovid 
Embase, EBSCO CINAHL Plus and Web of Science will 
be conducted to identify relevant papers published from 
inception to October 2017. The search strategy will be 
based on criteria set out by the Cochrane Collaboration 
in a recently published systematic review and is available 
in the online supplementary appendix.19 The Interna-
tional Standard Randomised Controlled Trial Number 
Registry, a primary clinical trial registry recognised by 
WHO and ICMJE that accepts and records all clinical 
research studies in order to improve the publicly avail-
able information about clinical studies, will also be 
searched for any relevant trials. Literature search results 
will be exported to EndNote and then uploaded to COVI-
DENCE, a web-based software that facilitates collabora-
tion among reviewers during the study selection process. 
Full-text articles will be uploaded to COVIDENCE. Two 
reviewers (HH and TB) will independently assess articles 
to determine eligibility for inclusion and any discrepan-
cies will be resolved by discussion or referred to a third 
reviewer (BS). Reference lists of included articles will be 
reviewed to identify other potential papers not retrieved 
in the initial search. Contributing authors and content 
experts will be asked if they have, or are aware of, any 
additional studies (published or unpublished).
risk of bias assessment and certainty of evidence 
assessment
Two reviewers will independently assess the risk of bias 
of each included study. RCTs will be assessed using the 
Cochrane risk of bias tool that includes items on allo-
cation bias (random sequence generation, allocation 
concealment, baseline imbalance), departures from 
intended interventions (participant and study personnel 
blinding, deviations from intended interventions and 
analysis in groups to which they were randomised), 
attrition bias and appropriate methods to account for 
missing data, detection bias (blinding of outcome asses-
sors) and selective outcome reporting.20 21 The “Risk 
Of Bias In Non-randomised Studies - of Interventions” 
(ROBINS-I) tool will be used to assess quality of each 
observational study. The ROBINS-I tool contains items on 
bias due to confounding, selection bias, bias due to devi-
ations from intended intervention, bias due to missing 
data and selective reporting.22 We will use GRADE to rate 
the overall certainty (quality) of evidence that includes 
the evaluation of risk of bias, inconsistency, indirectness, 
imprecision and publication factors.23
data extraction and database creation
Authors of eligible trials and observational studies will be 
contacted via an email, or where this is not possible by 
a letter, outlining the study aims. They will be invited to 
collaborate and share their data in a format of their choice. 
A data sharing agreement may be provided on request. 
A complete database (containing data on all available 
measures) rather than key variables used in the publica-
tion will be requested. If resource usage and quality of 
life data were collected in separate forms, such informa-
tion should be provided too. This will allow us to recalcu-
late the primary outcomes where necessary to ensure a 
consistent approach has been used across studies with the 
aim of reducing the level of between-study heterogeneity. 
Collaborators will be able to provide the data in a format 
of their choice. Study data will be considered unavailable 
in the event that none of the authors have responded to 
multiple contact attempts or if all contacted study authors 
indicate they no longer have access to the data.
Data will be checked by comparing key variables (eg, 
size of sample, descriptive statistics of demographic 
and outcome measures) with published data. We will 
aim to reproduce individual study results to ensure the 
current analysis is consistent with what has been done in 
each study. Collaborators will be contacted if important 
discrepancies are identified and asked for clarification. 
The level of missing data within each included study will 
be assessed and discussed with study collaborators. If less 
than 5% of data is found to be missing on key baseline 
characteristics and outcome measures, the data will be 
analysed on a complete cases basis. However, if there is 
substantial missing data, the pattern and nature of the 
missingness will be explored and multiple imputation by 
chained equations will be used if appropriate.
A copy of the data to be included in the IPD meta-anal-
ysis will be converted for analysis in STATA V.14 or above. 
A database will be created containing study ID, patient 
ID, outcomes measures, subgroups of interest, antibiotic 
prescribing approach and propensity scores, where neces-
sary. Outcome measures from the different studies will be 
harmonised once data from all study authors have been 
received. In the case that coding for an outcome in a 
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study differs greatly from other studies, it may be possible 
to simplify measures to allow the study to contribute data 
or exclude the study from certain analyses. Any difficul-
ties with harmonisation will be discussed with the full 
collaborators group to decide on the most meaningful 
approach. Harmonised data from the different studies 
will be aggregated (using STATA) into a single large IPD 
database, with an indicator variable to identify patients 
from the same trial. The IPD database will be rechecked 
for accuracy.
The key resource information on medication, primary 
care consultation, hospital inpatients, hospital day cases, 
outpatient visits, accident and emergency (A&E) atten-
dance from individual studies will be recorded if such 
information were collected and length of usage and 
frequency of attendance will be adjusted to the same 
time periods. We will use the UK national published tariff 
(British National Formulary (BNF), national reference 
cost and PSS Research Unit (PSSRU)) to cost-associated 
resource usage.
Analysis
Study and patient level characteristics will be described 
for all studies that contribute IPD. Characteristics of any 
studies that declined or were unable to provide data will 
be considered in order to determine the extent to which 
the included studies are a representative sample. A tradi-
tional meta-analysis may be performed, using data from 
published papers, to test for differences between studies 
included in the IPD meta-analysis and those that could 
not provide data.24
Heterogeneity of eligible studies will be summarised 
using an I2 statistic (tested by Higgins I2 test). A substan-
tial statistical heterogeneity will be considered if I² statistic 
is >50%.21 Sources of heterogeneity will be explored and 
reported and a random effects model will be used for all 
analyses.
IPD meta-analysis
IPD meta-analysis will be conducted using a one-stage 
approach. The one-stage approach combines all the data 
in a single meta-analysis based on a regression model 
stratified by study.25 One-stage analysis is often more 
appropriate for exploring treatment-covariate interac-
tions as it has increased power and is less likely to suffer 
from aggregation bias.26 The aggregated IPD will be 
examined using multilevel regressions clustering on the 
individual study level to take into account any heteroge-
neity between studies. Using the aggregated IPD dataset, 
we will calculate the key outcome measures on a consis-
tent basis. The model selected will be one that is appro-
priate to the outcome measure of interest. For example, 
assuming the underlying assumptions of the model are 
met, a linear regression will be used to model the severity 
of symptoms, a proportional-hazards model will be used 
to assess the duration of illness, or a suitable count model 
where time to event data is not available, and logistic 
regression models will be used for the complications/
reconsultation outcome, side effects and patient satisfac-
tion. All models will control for baseline severity of illness 
and all individuals will be included on a modified inten-
tion to treat (ITT) basis (ie, as randomised).27
To explore whether there are differences in treat-
ment effects for certain sub-groups, we will consider five 
prespecified subgroups which have been identified as 
potential effect modifiers by previous research: prior dura-
tion of illness (above/below median for the condition), 
age (under 16 years, 16–64 years, age over 65 years), fever 
at baseline consultation (>37.5°C), comorbid condition 
including lung comorbidity such as asthma or COPD, and 
severity of symptoms at baseline consultation. We will also 
explore differences according to the diagnostic group 
(acute sore throat, cough/chest infection, otalgia/otitis 
media, upper RTI). The analyses described above will be 
repeated, testing for interactions between treatment allo-
cation and sub-group characteristic.
Symptom trajectories in patients who do not take anti-
biotics will also be explored. For symptoms recorded in 
symptom diaries, we will calculate the median and IQR 
of the reported time until all symptoms have settled 
completely, in those patients who did not receive an anti-
biotic prescription or who received a delayed prescrip-
tion but did not fill it (where these data are available). 
As sensitivity analyses, we will also explore duration of 
moderately severe of symptoms. It is possible that the use 
of multiple outcomes (symptom severity, development of 
complications, patient satisfaction) to determine clinical 
effectiveness may result in varying conclusions. We will 
report the results for each outcome, though the discus-
sion and recommendations will be based primarily on the 
primary outcome– symptom severity.
Work on cross design synthesis by the Program and 
Methodology Division of the US General Accounting 
Office (1992) has provided a theoretical framework for 
combining database data and RCT data. Drawing on this 
work, the current review will apply a similar approach 
to the synthesis of observational cohort and RCT data.28 
Synthesis of observational studies will additionally use 
inverse probability weighting by propensity score anal-
ysis to adjust for confounding by indication on measured 
covariates. This serves to balance observational studies on 
key covariates) so that the distribution of baseline covari-
ates is similar between treated and untreated subjects, 
making observational studies more like those in a RCT.29 30 
Potential covariates to be included in the propensity score 
include: demographic factors (eg, age, sex), comorbid 
health conditions and signs and symptoms at baseline 
consultation. Observational studies after this adjustment 
for potential confounding variables will be included in 
the main analysis if appropriate. However, sensitivity 
analyses will explore whether the estimates from observa-
tional cohort studies differ from those found in the RCTs. 
If there is evidence of substantial differences, data from 
observational studies and RCTs will not be pooled in a 
single meta-analysis, and reasons for these differences will 
be explored narratively.
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Economic analysis
The economic evaluation will be taken from the NHS and 
PSS perspective, as most of the studies in this area have 
collected such data. The NHS and PSS perspective is the 
most commonly used approach to economic evaluations 
conducted in the UK. It covers medication, primary care 
consultation, walking in centre, NHS telephone service, 
outpatient attendance, A&E visit and hospital admis-
sion. Outcomes will be differences in cost, costs per anti-
biotic prescription avoided and costs per quality of life 
gained. Individual patient resource usage data such as 
medication use, GP consultations, outpatient visits, A&E 
attendance and use of secondary care service from each 
individual trial or observational study will be costed using 
UK published data sources (BNF, national reference costs 
and PSSRU). Total costs for individual patients during 
study periods will be calculated. We will also take a soci-
etal perspective by including the societal cost of antimi-
crobial resistance and time of work due to illness in our 
modelling and sensitivity analyses.
A decision analytical model will be developed to project 
the potential saving (due to reduced antibiotic usage, and 
reduced frequency of attending primary care consulta-
tion) and cost-effectiveness in terms of reduced antibiotic 
usage, and quality-adjusted life years (QALY) gained of 
delayed antibiotics. The model will consider reinfection 
and present the results at different time lengths, up to 
a maximum of 5 years. The model will be an individu-
al-based micro-simulation taking into account individual 
risk profiles with associated risk equations. The model 
will simulate individual treatment pathways with defined 
baseline characteristics and will capture the time spent at 
different levels of disease severity, time to recovery and 
recurrence rates. The probabilities of staying or transi-
tioning to another state will be derived from the statis-
tical analyses. The clinical analyses based on all data will 
provide more robust estimates to populate the input 
values for the data. The costs and cost-effectiveness of 
subgroups will be explored in the decision model.
Quality of life questionnaire will be translated into 
utility scores based on the UK tariff appropriate to the 
instruments used in each study. The different instruments 
(such as EQ5D, SF6D or Health Utilities Index (HUI)) 
will be recorded and weighted in the aggregated anal-
yses. Utility scores at each measurement point will be esti-
mated, and a mean utility score for symptom severity will 
be calculated. For studies where no quality of life data 
were collected, we will apply the utility scores estimated 
from the other studies according to symptom severity. 
QALYs will be calculated based on an area under the 
curve approach. Due to the potentially skewed distribu-
tion in costs, a generalised linear mixed model will be 
employed to analyse costs and QALYs, controlling for 
baseline patient characteristics, length of follow-up and 
disease severity. The data will be hierarchical, with indi-
vidual patients nested within studies, with study modelled 
as a random effect. Incremental costs and cost-effective-
ness and associated CIs will be estimated by bootstrapping. 
The economic analyses will follow the same approach as 
the statistical analyses with calculations undertaken using 
a one-stage approach.
Sensitivity analyses
All analyses will be repeated using a two-step approach. 
The two-stage approach involves calculating the effect 
for each study separately and then combining the results 
using traditional meta-analysis techniques. Results using 
the one-stage and two-stage approach will be compared 
and any discrepancies explored. This will also allow us to 
include and explore the impact of the aggregate results 
from trials for which we are unable to obtain data, as aggre-
gate results can only be included in a two-step approach. 
Aggregated data from observational studies will not be 
included because in the absence of full data, it will not be 
possible to control for confounding by indication.
Sensitivity analysis will explore whether there are differ-
ences in inferences based on differences in the approach 
taken to delayed prescribing and whether there are any 
differences if studies at high risk of bias are excluded. We 
will also consider a higher cut-off for presence of fever 
informed by the literature.
Given the potential long-term problem of antibi-
otic resistance, a sensitivity analysis will performed to 
incorporate the costs of antibiotic resistance in the 
economic analyses. However, given the difficulty previous 
researchers31 32 have had in estimating such costs we will 
vary the assumptions about the likely cost to see whether 
the inferences are modified.
Patient and public involvement
The study has two patient and public involvement (PPI) 
team members who have been actively involved in shaping 
the research questions and will continue to contribute to 
all stages of the research. Specifically, they will contribute 
to data harmonisation, providing advice to ensure the 
result will yield useful outcomes for patients and members 
of the public, interpretation of study findings and what 
they might mean for patients and the public, dissemina-
tion at relevant conferences/meetings and how best to 
disseminate findings to key patient and public groups. 
In return for their time, PPI representatives will be reim-
bursed in line with INVOLVE recommendations33 and 
will be recognised as co-authors on research outputs.
Ethics and dissemination
There will be no identifiable patient data in any of the 
datasets, and data will be stored in a password-restricted 
folder on the university server. This protocol has been 
prepared in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses Protocol 
guidelines.34
The results of this work will provide the best possible 
evidence regarding when and for whom delayed 
prescribing is appropriate. The results, disseminated 
through academic and trade journals, as well as confer-
ences, should help GPs in their decision-making about 
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prescribing during consultations. The results will also be 
shared with patients and members of the public through 
our PPI collaborations. There is potential for PPI to help 
address the issue of patients seeking antibiotics inappro-
priately which may help reduce unnecessary prescribing 
and in turn, antimicrobial resistance.
dIsCussIOn
IPD meta-analysis is more appropriate and has higher 
statistical power than traditional meta-analysis to identify 
which key subgroups or patient characteristics may or may 
not benefit from delayed prescribing. Another advan-
tage of IPD is that some of the biases in studies can be 
explored more fully than in aggregate data meta-analysis. 
For example, it is possible to check the randomisation 
integrity and to perform a full ITT analysis to minimise 
attrition bias, even if this was not performed for the orig-
inal publication. Furthermore, with the collaboration and 
communication required for a successful IPD, it should 
be possible to obtain information from the original study 
authors about potential sources of bias. A further advan-
tage of IPD meta-analysis is that it allows study outcomes 
to be calculated in the same way and the models adjusted 
for similar confounders which can reduce heterogeneity 
across studies.
However, there are some challenges associated with 
IPD meta-analysis.35 The key risk is not obtaining all the 
relevant data and failure to do so can result in biased 
results. It may be particularly difficult to obtain data for 
older studies, as the data may have been lost or destroyed 
or the lead researcher may have retired or changed field. 
We therefore plan to undertake a sensitivity analysis using 
a two-step approach which will allow us to incorporate 
the published estimates from any trials for which we are 
unable to obtain IPD into a meta-analysis. Although IPD 
offers the ability to conduct additional and more accu-
rate and appropriate analyses, in many cases similar 
results and conclusions can be drawn from IPD and stan-
dard meta-analysis.35 It is also possible that the outcome 
measures may not be sufficiently similar to harmonise. 
An initial scoping review suggests that almost all studies 
have collected the key outcome measures in a similar 
way. However, if it is deemed impossible to perform 
a meta-analysis with the data; a narrative review will be 
undertaken instead. We hope the results of the study will 
help GPs to communicate more effectively with patients 
about the normal course of illness, which patients are 
likely to benefit from a delayed prescribing approach, the 
costs of antibiotic use for RTIs and help the general public 
to feel more confident about waiting to see whether their 
illness settles before visiting their GP.
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